- Pfizer released data Nov. 22 showing its COVID-19 vaccine was 100 percent effective at preventing disease among recipients ages 12-15, measured from seven days to four months after they received their second shot.
- A study published Dec. 1 in The New England Journal of Medicine showed that Moderna’s COVID-19 vaccine was slightly more effective than Pfizer’s at preventing disease and subsequent negative outcomes among U.S. veterans.
- A study published Dec. 2 in The Lancet showed that the COVID-19 vaccines made by Pfizer and Moderna are most effective at boosting antibody levels among fully vaccinated adults.
- A small study published Dec. 5 in the preprint server MedRxiv showed that people who received two doses of Pfizer’s COVID-19 vaccine might get the same increase in immunity from a Johnson & Johnson booster dose as one from Pfizer.
- Pfizer said Dec. 8 its COVID-19 booster provided significant protection against the omicron variant during a laboratory study.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
